Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 539-543

  Brooks, Rebecca ^a   Kizer, Nora ^a   Nguyen, Loan ^a   Jaishuen, Atthapon ^a,b   Wanat, Karolyn ^a,c   Nugent, Elizabeth ^a   Grigsby, Perry ^d   Allsworth, Jenifer E ^a   Rader, Janet S ^a  

^a BARNES JEWISH HOSPITAL   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical cancer; Metastases; MMP9; SIPA1; SNPs

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE B; GENOMIC DNA; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; SIGNAL INDUCED PROLIFERATION ASOCIATED GENE 1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER INVASION; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; EARLY CANCER; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PELVIS LYMPH NODE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER;

ALLELES; CASE-CONTROL STUDIES; FEMALE; GTPASE-ACTIVATING PROTEINS; HUMANS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MATRIX METALLOPROTEINASE 9; NEOPLASM STAGING; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; UTERINE CERVICAL NEOPLASMS;

EID: 75749152523     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.037     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. CA Cancer J Clin 58 2 (2008) 71-96
2. Plummer M., and Franceschi S. Strategies for HPV prevention. Virus Res. 89 (2002) 285-293
3. Kosary C.L. Cancer of the cervix uteri. In: Ries L., Keel G.E., Eisner M.P., Lin Y.D., and Horner M.-J. (Eds). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Progra, 1988-2001, Patient and Tumor Characteristics (2007), Bethesda, MD, National Cancer Institute, SEER Program 111-121
4. Hricak H., Gatsonis C., Chi D.S., Amendola M.A., Brandt K., Schwartz L.H., et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J. Clin. Oncol. 23 (2005) 9329-9337
5. Delgado G. Stage IB squamous cancer of the cervix: the choice of treatment. Obstet. Gynecol. Surv. 33 (1978) 174-183
6. Hsieh S.M., Lintell N.A., and Hunter K.W. Germline polymorphisms are potential metastasis risk and prognosis markers in breast Cancer. Breast Dis. 26 (2006) 157-162
7. Hunter K. The intersection of inheritance and metastasis: the role and implications of germline polymorphism in tumor dissemination. Cell Cycle 4 (2005) 1719-1721
8. Ramaswamy S., Ross K.N., Lander E.S., and Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33 (2003) 49-54
9. Hunter K.W. Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination. Cancer Lett. 200 (2003) 97-105
10. Ji J., Forsti A., Sundquist J., Lenner P., and Hemminki K. Survival in bladder and renal cell cancers is familial. J. Am. Soc. Nephrol. 19 5 (2008) 985-991
11. Hunter K.W., and Crawford N.P. Germ line polymorphism in metastatic progression. Cancer Res. 66 (2006) 1251-1254
12. Crawford N.P., Ziogas A., Peel D.J., Hess J., Anton-Culver H., and Hunter K.W. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast Cancer. Breast. Cancer Res. 8 (2006) R16
13. Nakamura T., Kuwai T., Kim J.S., Fan D., Kim S.J., and Fidler I.J. Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia 9 (2007) 979-986
14. Chantrain C.F., Shimada H., Jodele S., Groshen S., Ye W., Shalinsky D.R., et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 64 (2004) 1675-1686
15. Hu Z., Huo X., Lu D., Qian J., Zhou J., Chen Y., et al. Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung Cancer. Clin. Cancer Res. 11 (2005) 5433-5439
16. Cotignola J., Reva B., Mitra N., Ishill N., Chuai S., Patel A., et al. Matrix metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. BMC. Med. Genet. 8 (2007) 10
17. Tang Y., Zhu J., Chen L., Zhang S., and Lin J. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric Cancer. Clin. Cancer Res. 14 (2008) 2870-2877
18. Deryugina E.I., Zijlstra A., Partridge J.J., Kupriyanova T.A., Madsen M.A., Papagiannakopoulos T., et al. Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res. 65 (2005) 10959-10969
19. Wong F.H., Huang C.Y., Su L.J., Wu Y.C., Lin Y.S., Hsia J.Y., et al. Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasis network for esophageal squamous cell carcinoma. Int. J. Oncol. 34 (2009) 117-128
20. Dunne A.A., Mandic R., Falkenberg S., Dalchow C.V., Sesterhenn A.M., and Werner J.A. RT-PCR expression profiling of matrix metalloproteinases and their specific inhibitors in cell lines and fresh biopsies of squamous cell carcinomas of the head and neck. In. Vivo. 19 (2005) 943-948
21. Mendes O., Kim H.T., and Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin. Exp. Metastasis. 22 (2005) 237-246
22. Inoue T., and Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer 65 (1990) 1923-1927
23. Tanaka Y., Sawada S., and Murata T. Relationship between lymph node metastases and prognosis in patients irradiated postoperatively for carcinoma of the uterine cervix. Acta. Radiol. Oncol. 23 (1984) 455-459
24. Keys H.M., Bundy B.N., Stehman F.B., Okagaki T., Gallup D.G., Burnett A.F., et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol. Oncol. 89 (2003) 343-353
25. Rotman M., John M.J., Moon S.H., Choi K.N., Stowe S.M., Abitbol A., et al. Limitations of adjunctive surgery in carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys. 5 (1979) 327-332
26. O'Quinn A.G., Fletcher G.H., and Wharton J.T. Guidelines for conservative hysterectomy after irradiation. Gynecol. Oncol. 9 (1980) 68-79
27. Zhang Z., Borecki I., Nguyen L., Ma D., Smith K., Huettner P.C., et al. CD83 gene polymorphisms increase susceptibility to human invasive cervical Cancer. Cancer Res. 67 (2007) 1202-1208
28. Westfall P.H., and Young S.S. Examples and methods for p-value adjustment. Resampling-Based Multiple Testing (1993), John Wiley and Sons
29. Kurachi H., Wada Y., Tsukamoto N., Maeda M., Kubota H., Hattori M., et al. Human SPA-1 gene product selectively expressed in lymphoid tissues is a specific GTPase-activating protein for Rap1 and Rap2. Segregate expression profiles from a rap1GAP gene product. J. Biol. Chem. 272 (1997) 28081-28088
30. Tsukamoto N., Hattori M., Yang H., Bos J.L., and Minato N. Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion. J. Biol. Chem. 274 (1999) 18463-18469
31. Lin P.I., Vance J.M., Pericak-Vance M.A., and Martin E.R. No gene is an island: the flip-flop phenomenon. Am. J. Hum. Genet. 80 (2007) 531-538
32. Zaykin D.V., and Shibata K. Genetic flip-flop without an accompanying change in linkage disequilibrium. Am. J. Hum. Genet. 82 (2008) 794-796 author reply 796-7
33. Yu C., Pan K., Xing D., Liang G., Tan W., Zhang L., et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung Cancer. Cancer Res. 62 (2002) 6430-6433
34. Yu C., Zhou Y., Miao X., Xiong P., Tan W., and Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal Cancer. Cancer Res. 64 (2004) 7622-7628
35. Zhang J., Jin X., Fang S., Li Y., Wang R., Guo W., et al. The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis 25 (2004) 2519-2524
36. Decock J., Long J.R., Laxton R.C., Shu X.O., Hodgkinson C., Hendrickx W., et al. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 67 (2007) 10214-10221
37. Zhang B., Henney A., Eriksson P., Hamsten A., Watkins H., and Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum. Genet. 105 (1999) 418-423
38. Shipley J.M., Doyle G.A., Fliszar C.J., Ye Q.Z., Johnson L.L., Shapiro S.D., et al. The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. J. Biol. Chem. 271 (1996) 4335-4341